Peringatan Keamanan

There are not reports of long-term studies regarding tumorgenesis or carcinogenesis. Fertility studies performed in aminal trials showed no adverse histopathological findings.FDA label

Benralizumab

DB12023

biotech approved investigational

Deskripsi

Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils and basophils.A31294 It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking signal transduction. It is an afucosylated IgG which gives it high affinity for the Fc?RIII? receptor in natural killer cells, macrophages and neutrophils.A31293

Benralizumab was FDA approved on November 14, 2017, and was developed by MedImmune, AstraZeneca's global biologic research and development arm.L1019

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The half-life of Benralizumab is estimated to be 15-18 days.[A31293]
Volume Distribusi Pharmacokinetic reports of Benralizumab showed a volume of distribution in a range of 52-93ml/kg. For a 70kg individual, the central volume of distribution of Benralizumab is 3.2 L while the peripheral volume of distribution is reported to be 2.5 L.[A31297]
Klirens (Clearance) For a subject weighting 70kg, the typical systemic clearance is 0.29L/day.[FDA label]

Absorpsi

Subcutaneous administration of Benralizumab presented a dose-proportional pharmacokinetic profile. The administration of 20-200 mg presented an absorption half-life of 3.6 days with a bioavailability of 58%.FDA label It is also reported for Benralizumab a Cmax of 82 mcg/ml and AUC of 775 mcg day/ml.A31293

Metabolisme

As any monoclonal IgG antibody, Beralizumab is degraded by proteases widely spread in the body. FDA label

Rute Eliminasi

Benraluzimab presents a linear pharmacokinetic without target-receptor mediated clearance.FDA label The presence of a dose-proportional pharmacokinetics suggests a rapid depletion of the target and an elimination mainly mediated through the reticuloendothelial system.A31297

Interaksi Obat

373 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Benralizumab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Benralizumab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Benralizumab.
Estrone Estrone may increase the thrombogenic activities of Benralizumab.
Estradiol Estradiol may increase the thrombogenic activities of Benralizumab.
Dienestrol Dienestrol may increase the thrombogenic activities of Benralizumab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Benralizumab.
Mestranol Mestranol may increase the thrombogenic activities of Benralizumab.
Estriol Estriol may increase the thrombogenic activities of Benralizumab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Benralizumab.
Quinestrol Quinestrol may increase the thrombogenic activities of Benralizumab.
Hexestrol Hexestrol may increase the thrombogenic activities of Benralizumab.
Tibolone Tibolone may increase the thrombogenic activities of Benralizumab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Benralizumab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Benralizumab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Benralizumab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Benralizumab.
Zeranol Zeranol may increase the thrombogenic activities of Benralizumab.
Equol Equol may increase the thrombogenic activities of Benralizumab.
Promestriene Promestriene may increase the thrombogenic activities of Benralizumab.
Methallenestril Methallenestril may increase the thrombogenic activities of Benralizumab.
Epimestrol Epimestrol may increase the thrombogenic activities of Benralizumab.
Moxestrol Moxestrol may increase the thrombogenic activities of Benralizumab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Benralizumab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Benralizumab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Benralizumab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Benralizumab.
Biochanin A Biochanin A may increase the thrombogenic activities of Benralizumab.
Formononetin Formononetin may increase the thrombogenic activities of Benralizumab.
Estetrol Estetrol may increase the thrombogenic activities of Benralizumab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Benralizumab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Benralizumab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Benralizumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Benralizumab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Benralizumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Benralizumab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Benralizumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Benralizumab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Benralizumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Benralizumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Benralizumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Benralizumab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Benralizumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Benralizumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Benralizumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Benralizumab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Benralizumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Benralizumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Benralizumab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Benralizumab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Benralizumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Benralizumab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Benralizumab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Benralizumab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Benralizumab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Benralizumab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Benralizumab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Benralizumab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Benralizumab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Benralizumab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Benralizumab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Benralizumab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Benralizumab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Benralizumab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Benralizumab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Benralizumab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Benralizumab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Benralizumab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Benralizumab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Benralizumab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Benralizumab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Benralizumab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Benralizumab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Benralizumab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Benralizumab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Benralizumab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Benralizumab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Benralizumab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Benralizumab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Benralizumab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Benralizumab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Benralizumab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Benralizumab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Benralizumab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Benralizumab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Benralizumab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Benralizumab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Benralizumab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Benralizumab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Benralizumab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Benralizumab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Benralizumab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Benralizumab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Benralizumab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Benralizumab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Benralizumab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Benralizumab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Benralizumab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Benralizumab.
Lumiliximab The risk or severity of adverse effects can be increased when Lumiliximab is combined with Benralizumab.

Target Protein

Interleukin-5 receptor subunit alpha IL5RA
Low affinity immunoglobulin gamma Fc region receptor III-A FCGR3A

Referensi & Sumber

Artikel (PubMed)
  • PMID: 22136436
    Ghazi A, Trikha A, Calhoun WJ: Benralizumab--a humanized mAb to IL-5Ralpha with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012 Jan;12(1):113-8. doi: 10.1517/14712598.2012.642359. Epub 2011 Dec 5.
  • PMID: 23866823
    Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, Busse WW, Wenzel S, Wu Y, Datta V, Kolbeck R, Molfino NA: Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013 Nov;132(5):1086-1096.e5. doi: 10.1016/j.jaci.2013.05.020. Epub 2013 Jul 16.
  • PMID: 28913336
    Bagnasco D, Ferrando M, Varricchi G, Puggioni F, Passalacqua G, Canonica GW: Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma. Front Med (Lausanne). 2017 Aug 31;4:135. doi: 10.3389/fmed.2017.00135. eCollection 2017.
  • PMID: 27110133
    Tan LD, Bratt JM, Godor D, Louie S, Kenyon NJ: Benralizumab: a unique IL-5 inhibitor for severe asthma. J Asthma Allergy. 2016 Apr 4;9:71-81. doi: 10.2147/JAA.S78049. eCollection 2016.
  • PMID: 28109128
    Wang B, Yan L, Yao Z, Roskos LK: Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma. CPT Pharmacometrics Syst Pharmacol. 2017 Apr;6(4):249-257. doi: 10.1002/psp4.12160. Epub 2017 Jan 21.

Contoh Produk & Brand

Produk: 7 • International brands: 0
Produk
  • Fasenra
    Injection, solution • 30 mg • Subcutaneous • EU • Approved
  • Fasenra
    Injection, solution • 30 mg • Subcutaneous • EU • Approved
  • Fasenra
    Injection, solution • 30 mg/1mL • Subcutaneous • US • Approved
  • Fasenra
    Injection, solution • 30 mg/1mL • Subcutaneous • US • Approved
  • Fasenra
    Injection, solution • 10 mg/0.5mL • Subcutaneous • US • Approved
  • Fasenra
    Solution • 30 mg / mL • Subcutaneous • Canada • Approved
  • Fasenra Pen
    Solution • 30 mg / mL • Subcutaneous • Canada • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul